These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
363 related articles for article (PubMed ID: 14667328)
1. Use of an oral contraceptive containing drospirenone in an extended regimen. Sillem M; Schneidereit R; Heithecker R; Mueck AO Eur J Contracept Reprod Health Care; 2003 Sep; 8(3):162-9. PubMed ID: 14667328 [TBL] [Abstract][Full Text] [Related]
2. A prospective follow-up of two 21/7 cycles followed by two extended regimen 84/7 cycles with contraceptive pills containing ethinyl estradiol and drospirenone. Seidman DS; Yeshaya A; Ber A; Amodai I; Feinstein I; Finkel I; Gordon N; Porat N; Samuel D; Shiran-Makler E; Wolman I Isr Med Assoc J; 2010 Jul; 12(7):400-5. PubMed ID: 20862819 [TBL] [Abstract][Full Text] [Related]
3. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives]. Cianci A; De Leo V Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Yonkers KA; Brown C; Pearlstein TB; Foegh M; Sampson-Landers C; Rapkin A Obstet Gynecol; 2005 Sep; 106(3):492-501. PubMed ID: 16135578 [TBL] [Abstract][Full Text] [Related]
5. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Apter D; Borsos A; Baumgärtner W; Melis GB; Vexiau-Robert D; Colligs-Hakert A; Palmer M; Kelly S Eur J Contracept Reprod Health Care; 2003 Mar; 8(1):37-51. PubMed ID: 12725674 [TBL] [Abstract][Full Text] [Related]
6. A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms. Brown C; Ling F; Wan J J Reprod Med; 2002 Jan; 47(1):14-22. PubMed ID: 11838304 [TBL] [Abstract][Full Text] [Related]
7. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being. Boschitsch E; Skarabis H; Wuttke W; Heithecker R Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():34-40. PubMed ID: 11246600 [TBL] [Abstract][Full Text] [Related]
8. Quality of life issues. Potential role for an oral contraceptive containing ethinyl estradiol and drospirenone. Dickerson V J Reprod Med; 2002 Nov; 47(11 Suppl):985-93. PubMed ID: 12497673 [TBL] [Abstract][Full Text] [Related]
9. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception. Borges LE; Andrade RP; Aldrighi JM; Guazelli C; Yazlle ME; Isaia CF; Petracco A; Peixoto FC; Camargos AF Contraception; 2006 Dec; 74(6):446-50. PubMed ID: 17157100 [TBL] [Abstract][Full Text] [Related]
11. Added benefits of drospirenone for compliance. Foidart JM Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653 [TBL] [Abstract][Full Text] [Related]
12. A prospective randomized trial comparing low-dose ethinyl estradiol and drospirenone 24/4 combined oral contraceptive vs. ethinyl estradiol and drospirenone 21/7 combined oral contraceptive in the treatment of hirsutism. Oner G; Muderris II Contraception; 2011 Nov; 84(5):508-11. PubMed ID: 22018126 [TBL] [Abstract][Full Text] [Related]
13. A study of cycle control, side effects and client's satisfaction of a low dose combined contraceptive containing ethinylestradiol/drospirenone (24/4 regimen). Chaiyasit N; Taneepanichskul S J Med Assoc Thai; 2010 May; 93(5):517-22. PubMed ID: 20524436 [TBL] [Abstract][Full Text] [Related]
14. Bleeding pattern, tolerance and patient satisfaction with a drospirenone-containing oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada. Endrikat JS; Milchev NP; Kapamadzija A; Georgievska J; Gerlinger C; Schmidt W; Feroze S Contraception; 2009 Jun; 79(6):428-32. PubMed ID: 19442777 [TBL] [Abstract][Full Text] [Related]
15. YAZ and the novel progestin drospirenone. Mishell DR J Reprod Med; 2008 Sep; 53(9 Suppl):721-8. PubMed ID: 18980044 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of a new oral contraceptive containing drospirenone. Shulman LP J Reprod Med; 2002 Nov; 47(11 Suppl):981-4. PubMed ID: 12497672 [TBL] [Abstract][Full Text] [Related]
17. Effects of an extended flexible regimen of an oral contraceptive pill containing 20 μg ethinylestradiol and 3 mg drospirenone on menstrual-related symptoms: a randomised controlled trial. Machado RB; Pompei LM; Badalotti M; Ferriani R; Cruz AM; Nahas E; Maia H Eur J Contracept Reprod Health Care; 2017 Feb; 22(1):11-16. PubMed ID: 27684740 [TBL] [Abstract][Full Text] [Related]
18. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen. Marr J; Gerlinger C; Kunz M Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):91-5. PubMed ID: 22391750 [TBL] [Abstract][Full Text] [Related]
19. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P Obstet Gynecol; 2008 Oct; 112(4):773-81. PubMed ID: 18827119 [TBL] [Abstract][Full Text] [Related]
20. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. Ahrendt HJ; Nisand I; Bastianelli C; Gómez MA; Gemzell-Danielsson K; Urdl W; Karskov B; Oeyen L; Bitzer J; Page G; Milsom I Contraception; 2006 Dec; 74(6):451-7. PubMed ID: 17157101 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]